Patheon enlarges dollar loan and cuts margins sharply
Toronto-listed pharmaceuticals firm Patheon has signed a new seven year covenant-lite loan package. A healthy oversubscription allowed it to increase the dollar tranche and substantially tighten price margins.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
